Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
This article was originally published in PharmAsia News
Executive Summary
Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.
You may also be interested in...
Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell
Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.